Replies to post #27086 on Seelos Therapeutics Inc (SEEL)

[OldtimeramI]

Still haven't heard the CC. At this point I am waiting for the transcript, I really don't feel like listening to Pascoe's voice at this time. I should thank him though, if what I am thinking is correct, I might be able to pick 3x my shares in the coming months and then cross my fingers, first for the acceptance of the NDA for review and then for the actual FDA decision around May 2018.

Not sure if I'm going to return the entirety of my funds though. I have pretty much already allocated the majority of them in other companies / sector. So far I'm doing good! Either way, I don't think I should be in any rush.

I had been a shareholder in Apricus for such a long time. I do remember the Secondary that you are talking about. If I remember correctly, there were like 3 shares per unit and one warrant ( something like that ).

Richard Pascoe sold the revenue generating business in order to be able to continue to dilute shareholders in the future.

I do understand the value of a FDA approval though, but I also understand that the best case scenario is an Allergan Opt-In in conjunction to said approval. It's not an automatic situation.

As far as the substantial liability goes. Have you read the 10K? I don't think that people here realize that not only Vitaros was part of the sale to Ferring but also the DDAIP patents.


As part of the Ferring Asset Purchase Agreement, we transferred the non-U.S. patents related to DDAIP and DDAIP in combination with alprostodil and received a perpetual, exclusive (even as to Ferring), fully transferable, fully sublicensable, royalty-free, fully paid-up license to such patents in certain fields other than sexual dysfunction.

Maybe the substantial liability is the upkeep cost of defending those patents worldwide? I read in one of those exhibits that it's very specific as to which indication ( drug candidate ) and which countries, Apricus gets to keep patent license for. It's not like Ferring only obtained ( alprostadil + DDAIP ) patents for ex-U.S. Vitaros through the sale. There might be a strategic reason for this. Who knows.